Navigation Links
Veteran International Health Care Executive Appointed CEO of BeneChill(R)
Date:6/4/2010

SAN DIEGO and STOCKHOLM, June 4 /PRNewswire/ -- Amgen executive Alan Raffensperger has been appointed the new Chief Executive Officer of BeneChill, a privately held medical device company launching its first product, a novel cooling device for use by emergency response teams in the field, later this year in Europe.  With more than 25 years of experience in the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger joins BeneChill from his post as Executive Director and Franchise Head of Nephrology for Amgen, a global biopharmaceutical company.  He joined Amgen in 2005 as General Manager of the Nordic and Baltic Region, overseeing operations in eight countries from his Sweden base.

(Photo:  http://photos.prnewswire.com/prnh/20100604/LA15970)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100604/LA15970)

"As we prepare to launch our lead RhinoChill™ product in Europe, it was critical that we recruit a seasoned, well-rounded CEO with big pharma experience and the sensitivity to a smaller company," said Denise Barbut, M.D., Executive Chair and founder of BeneChill. "Alan's stellar track record and experience in product development, sales and marketing will enable us to achieve our business goals."

Prior to Amgen, Mr. Raffensperger was with Hoffman La Roche for ten years with his most recent position as Head of Pharmaceutical Marketing and Sales for Roche in Sweden. Previously, he was the CEO for Swedemed, a privately-held developer of an advanced ultrasonic surgery system. He began his career with Pharmacia, first in sales in the U.S. and then product management in Sweden.

Earlier in his career, Mr. Raffensperger was a paramedic for National Hospital in Arlington, VA and notes that his experience in cardiovascular and trauma emergency care provides a solid foundation for understanding the need for BeneChill's cooling devices in the field.  He received his Bachelor of Science degree in Emergency Health Sciences Management from the University of Maryland and was an MBA candidate at George Washington University.  He is a nationally registered EMT-paramedic.

BeneChill® is a privately held medical device company that develops novel, rapid cooling systems to improve survival after cardiac arrest.  RhinoChill™ can be administered quickly and directly to the brain by a proprietary portable system that uses a nasal catheter to deliver a rapid evaporative coolant and will be marketed in Europe later this year. With corporate headquarters in San Diego, CA, BeneChill will be opening offices in Switzerland.  


'/>"/>
SOURCE BeneChill
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
2. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
3. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
4. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
5. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
6. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
7. NovaRx Appoints Industry Veteran as President and COO
8. For Iraq Veterans, Headaches Continue After Traumatic Brain Injury
9. Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and ... Dry eye market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global Dry ...
(Date:2/24/2017)... 2017 Juan Monteverde , founder and ... a boutique securities firm headquartered at the Empire State ... announces that a class action lawsuit has been filed in ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") ... 23, 2015 and December 30, 2016, inclusive (the "Class ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Liberty University, has officially announced the appointment of Peter A. Bell, DO, MBA, ... Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions ... so critically important that we all are aware of our options and are ... proud to announce the launch of its newest edition of "Vision and Hearing" ...
(Date:2/24/2017)... ... 2017 , ... With ProGlass Prism users now have the ability to simulate ... over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, ... ProGlass Prism users are given the tools and effects to generate a fractal ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
Breaking Medicine News(10 mins):